ACRV Acrivon Therapeutics, Inc.: חובות לטווח קצר של החברה

Acrivon Therapeutics (ACRV) possesses significant pricing power thanks to the APAM platform, which individualizes therapy based on proteomic profiles. The short-term debt history shows that the parameter value equals 0.00. The development of targeted molecules relies on AI and synthesis automation. Meanwhile, the laboratories efficiently identify biomarkers, maintaining reserved capacity for future mass production of drugs.

This indicator aggregates all obligations with a maturity of up to one year, allowing for an assessment of the company's liquidity and default risk over the short term. By analyzing total short-term liabilities, an investor can determine whether Acrivon Therapeutics (ACRV) possesses sufficient resources to fund current clinical trials of oncology drugs, confirming the asset's financial stability on the path toward medium-term catalysts.